Originally published by our sister publication, Anesthesiology News
Heron Therapeutics recently announced that the FDA approved a supplemental New Drug Application (sNDA) for its bupivacaine-meloxicam (Zynrelef) combination drug. The new indication is for soft tissue or periarticular instillation for postoperative analgesia of up to 72 hours after foot and ankle as well as small- to medium-sized open abdominal surgeries, and lower extremity total joint arthroplasties.
In phase 3 studies,